Revolution Medicines (RVMDW) Share-based Compensation (2019 - 2026)
Revolution Medicines (RVMDW) posted quarterly Share-based Compensation of $87.3 million for Q1 2026, up 248.03% year-over-year from $25.1 million in Q1 2025, and down 9.0% quarter-over-quarter from $95.9 million in Q4 2025.
Revolution Medicines (RVMDW) Share-based Compensation (2019 - 2026) Analysis & Trends
Revolution Medicines' Share-based Compensation history runs 8 years deep, the most recent figure standing at $87.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 248.03% year-over-year to $87.3 million; the TTM figure through Mar 2026 stood at $151.6 million (up 671.05% YoY), while the FY2025 annual figure was $208.4 million, up 75.42% from the prior year.
- Share-based Compensation for Q1 2026 stood at $87.3 million, down from $95.9 million in the prior quarter.
- The five-year high for Share-based Compensation was $178.5 million in Q2 2025, with the low at -$56.8 million in Q4 2024.
- The 5-year median for Share-based Compensation is $13.7 million (2023), against an average of $46.4 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation plunged 469.21% in 2022, then soared 814.48% in 2024.
- Revolution Medicines' Share-based Compensation stood at -$22.9 million in 2022, then jumped by 51.6% to -$11.1 million in 2023, then sank by 412.53% to -$56.8 million in 2024, then surged by 269.02% to $95.9 million in 2025, then fell by 9.0% to $87.3 million in 2026.
- Business Quant data shows RVMDW's Share-based Compensation at $87.3 million in Q1 2026, $95.9 million in Q4 2025, and $177.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Revolution Medicines | 2.59 Bn | 2.59 Bn | - | 277.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 277.20 Mn |
| Jun 30, 2026 | 277.20 Mn |
| Mar 31, 2026 | 87.30 Mn |
| Mar 31, 2026 | 87.30 Mn |
| Dec 31, 2025 | 95.93 Mn |
| Dec 31, 2025 | 95.93 Mn |
| Sep 30, 2025 | 177.70 Mn |
| Sep 30, 2025 | 177.70 Mn |
| Jun 30, 2025 | 178.50 Mn |
| Jun 30, 2025 | 178.50 Mn |
| Mar 31, 2025 | 25.08 Mn |
| Mar 31, 2025 | 25.08 Mn |
| Dec 31, 2024 | -56.76 Mn |
| Dec 31, 2024 | -56.76 Mn |
| Sep 30, 2024 | 120.80 Mn |
| Sep 30, 2024 | 120.80 Mn |
| Jun 30, 2024 | 118.70 Mn |
| Jun 30, 2024 | 118.70 Mn |
| Mar 31, 2024 | 16.21 Mn |
| Mar 31, 2024 | 16.21 Mn |